EFFECT OF PUTA IN ABHRAKA MARANA W.S.R. TO MADHUMEHA ( TYPE-2 DM )
Trial Snapshot
- Phase
- Phase 1/2
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- It is expected that the trial drugs will exert a significant action over classical symptomatology of Madhumeha (Prabhutamutrata, Avilamutrata)
Study Overview
Brief Summary
Almost all Rasavarga Dravya are used therapeutically essentially after Shodhana and Marana. Abhraka is one among the drugs which are said to use after proper process of *Marana.*Abhraka is among Rasavarga dravya for whome maximum number of repetitive cycles of Puta that is 1000 are mentioned in ancient classics on Rasa Shastra. Although Bhasma of Abhraka can be prepared with single Puta, yet 1000 repetitive cycles of Puta are also mentioned for its marana.
Abhraka is said to posses Pramehahara property and said to be used in all diseases. It is among few Rasavarga dravya which predominantly have Yogavahi and Rasayana property.In Prameha, 10 dushya gets affected hence drug posseing Rasayana property along with Pramehahara effect would be drug of choice, which Abhraka Bhasma.
Study Design
- Study Type
- Interventional
- Allocation
- Not Applicable
- Masking
- Not Applicable
Eligibility Criteria
- Ages
- 30.00 Year(s) to 60.00 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •Both the sexes having Age between 30 years to 60 years Patients having classical symptomatology of Madhumeha (Prabhutamutrata, Avilamutrata etc) Symptoms of Diabetes (Polyuria, Polydipsia, Polyphagia and Weight loss) Patients having Blood sugar Fasting Blood Sugar ≥ 126 mg/dl Post Prandial Blood Sugar ≥ 200 mg/dl.
Exclusion Criteria
- •Age below 30 and above 60 years.
- •Patients of Diabetes Mellitus receiving Insulin.
- •Malignant and accelerated Hypertension.
- •Patients having chronic complications of Diabetes Mellitus a.Microvascular: Retinopathy, Neuropathy, & Nephropathy.
- •b.Macrovascular: Coronary artery disease, Peripheral vascular disease & Cerebro-vascular disease.
- •c.Other chronic debilitating diseases like STD etc.
- •5.Pregnant women.
- •6.Lactating mothers.
- •7.Secondary Diabetes mellitus.
- •8.Patients of any other severe illness.
- •9.Severe Iron deficiency anemia with Hb% less than 7mg/dl.
Outcomes
Primary Outcomes
It is expected that the trial drugs will exert a significant action over classical symptomatology of Madhumeha (Prabhutamutrata, Avilamutrata)
Time Frame: up to 8 weeks
Secondary Outcomes
- It will help to live diabetic patient more healthy and without complications(Up to 4 weeks)